ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis’ Aimovig fails to win NICE backing amid tight migraine fight with Lilly, Teva
January 13, 2019Separately, the Institute for Clinical and Economic Review previously concluded that Aimovig’s use is cost-effective but only after patients try “existing preventive treatments, which are far less expensive.” -
Novartis’ Aimovig fails to win NICE backing amid tight migraine fight with Lilly, Teva
January 13, 2019Separately, the Institute for Clinical and Economic Review previously concluded that Aimovig’s use is cost-effective but only after patients try “existing preventive treatments, which are far less expensive.”
Pharma Sources Insight January 2025
